Clinical Trials Logo

Skin and Soft Tissue Infections clinical trials

View clinical trials related to Skin and Soft Tissue Infections.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05270135 Completed - Hiv Clinical Trials

ASAP: Access to Syringes at Pharmacies for the Prevention of Bloodborne Infections Among People Who Inject Drugs

ASAP
Start date: December 1, 2022
Phase: N/A
Study type: Interventional

Access to Syringes at Pharmacies (ASAP) is a refinement of an evidence-based, pharmacy intervention to increase pharmacy-based sales of syringes to PWID in order to reduce bloodborne illnesses among them.

NCT ID: NCT03744741 Completed - Sepsis Clinical Trials

HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study

Start date: July 23, 2018
Phase:
Study type: Observational

This study will analyze gene expression data (HostDx Sepsis test) from blood samples collected from participants with suspected infections. The primary endpoint of the study is to prospectively validate the HostDx Sepsis test for infections. As a secondary endpoint the correlation of participant prognosis and gene expression results in the HostDx Sepsis test will be validated. Participants presenting to the emergency departments of enrolling sites with a suspected infection and 1 vital signs OR suspected sepsis and 2 vital sign changes as stated in the protocol are meeting enrollment criteria

NCT ID: NCT01037192 Completed - Clinical trials for Skin and Soft Tissue Infections

Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections

VOD
Start date: March 2010
Phase: N/A
Study type: Interventional

Our hypothesis is that large-dose, extended-interval vancomycin (30 mg/kg IV q24h) administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin (15 mg/kg IV q12h) administration for skin and soft tissue infections in an outpatient setting.

NCT ID: NCT00989872 Completed - Clinical trials for Methicillin-resistant Staphylococcus Aureus

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

Start date: n/a
Phase: Phase 1
Study type: Interventional

This was a randomized, double-blind, placebo-controlled, ascending single dose safety, tolerability, and pharmacokinetic study of orally administered EDP-322. This study was conducted at a single site. EDP-322 has a benefit to risk profile that supports testing in target patient populations.